Haleon plc (HLN)
NYSE: HLN · Real-Time Price · USD
10.07
+0.04 (0.40%)
At close: Sep 1, 2026, 4:00 PM EDT
9.94
-0.13 (-1.29%)
Pre-market: Sep 2, 2026, 7:21 AM EDT
Haleon Revenue
Haleon had revenue of 5.60B GBP in the half year ending June 30, 2026, a decrease of -1.62%. This brings the company's revenue in the last twelve months to 11.15B, up 1.21% year-over-year. In the year 2025, Haleon had annual revenue of 11.03B, down -1.81%.
Revenue (ttm)
11.15B GBP
Revenue Growth
+1.21%
P/S Ratio
2.98
Revenue / Employee
454,534 GBP
Employees
24,535
Market Cap
44.08B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.03B | -203.00M | -1.81% |
| Dec 31, 2024 | 11.23B | -69.00M | -0.61% |
| Dec 31, 2023 | 11.30B | 444.00M | 4.09% |
| Dec 31, 2022 | 10.86B | 1.31B | 13.76% |
| Dec 31, 2021 | 9.55B | -347.00M | -3.51% |
| Dec 31, 2020 | 9.89B | 1.41B | 16.65% |
| Dec 31, 2019 | 8.48B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.42B |
| Teva Pharmaceutical Industries | 17.32B |
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
HLN News
- 9 days ago - Haleon price target raised to 410 GBp from 400 GBp at Jefferies - TheFly
- 14 days ago - Haleon Completes Tender Offer For 2027 Notes, Sets Settlement For August 21 - Nasdaq
- 14 days ago - Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes - PRNewsWire
- 21 days ago - Haleon price target raised to 390 GBp from 370 GBp at RBC Capital - TheFly
- 21 days ago - Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes - PRNewsWire
- 26 days ago - Haleon price target raised to 460 GBp from 430 GBp at Morgan Stanley - TheFly
- 4 weeks ago - ACCO vs. HLN: Which Stock Is the Better Value Option? - Nasdaq
- 4 weeks ago - Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US - Reuters